Moreover, CXCL10 can recruit CXCR3+ tumor-infiltrating CD4+ T cells and CD8+ T cells that are likely to enhance anti-cancer response.23 To investigate how the CXCR3/CXCL10 axis involved T cells recruitment in the TME, we first confirmed CXCR3 expression in a 4-day induction sphere by flow cytometric analysis. The gene discussed is CD8A; the disease is neoplasm.